CoChat
Sign Up
Cited by 349Ferroptosis and cancer prognosisCancer, Lipids, and MetabolismIron Metabolism and Disorders

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4

Open access
Chen, Delin, Chu, Bo, Yang, Xin, Liu, Zhaoqi, Jin, Ying, Kon, Ning, Rabadan, Raul, Jiang, Xuejun, Stockwell, Brent R., Gu, Wei·2021·Nature Communications
DOI 10.1038/s41467-021-23902-6PMC PMC8206155
Open this paper in CoChat — free accountOpen PDF

Abstract

Here, we identify iPLA2β as a critical regulator for p53-driven ferroptosis upon reactive oxygen species (ROS)-induced stress. The calcium-independent phospholipase iPLA2β is known to cleave acyl tails from the glycerol backbone of lipids and release oxidized fatty acids from phospholipids. We found that iPLA2β-mediated detoxification of peroxidized lipids is sufficient to suppress p53-driven ferroptosis upon ROS-induced stress, even in GPX4-null cells. Moreover, iPLA2β is overexpressed in human cancers; inhibition of endogenous iPLA2β sensitizes tumor cells to p53-driven ferroptosis and promotes p53-dependent tumor suppression in xenograft mouse models. These results demonstrate that iPLA2β acts as a major ferroptosis repressor in a GPX4-independent manner. Notably, unlike GPX4, loss of iPLA2β has no obvious effect on normal development or cell viability in normal tissues but iPLA2β plays an essential role in regulating ferroptosis upon ROS-induced stress. Thus, our study suggests that iPLA2β is a promising therapeutic target for activating ferroptosis-mediated tumor suppression without serious toxicity concerns.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-23902-6

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 p53-Mediated ferroptosis is GPX4-independent upon ROS-induced stress. a Western blot analysis of U2OS ACSL4−/−; GPX4−/− cells treated with Nutlin (10 μM) as indicated for 48 h. The experiments were repeated twice, independently, with similar results. b U2OS ACSL4−/−; GPX4−/− cells were treated with Erastin (40 μM) and Ferr-1 (2 μM) as indicated for 12 h. c U2OS ACSL4−/−; GPX4−/− cells were treated with RSL-3 (2 μM) and Ferr-1 (2 μM) as indicated for 12 h. d U2OS control, ACSL4−/−; GPX4−/− cells pre-incubated with Nutlin (10 μM) for 24 h were treated with TBH (250 μM), Nutlin (10 μM), Ferr-1 (2 μM), Lipro-1 (2 μM), 3-MA (2 mM), necrostatin-1 (10 μg/mL), and Z-VAD-FMK (10 μg/mL) as indicated, for 8 h. 3-MA, 3-methylademine. b–d Error bars are mean ± s.d., n = 3 biologically independent experiments. Source data are provided as a Source Data file.
Fig. 1 p53-Mediated ferroptosis is GPX4-independent upon ROS-induced stress. a Western blot analysis of U2OS ACSL4−/−; GPX4−/− cells treated with Nutlin (10 μM) as indicated for 48 h. The experiments were repeated twice, independently, with similar results. b U2OS ACSL4−/−; GPX4−/− cells were treated with Erastin (40 μM) and Ferr-1 (2 μM) as indicated for 12 h. c U2OS ACSL4−/−; GPX4−/− cells were treated with RSL-3 (2 μM) and Ferr-1 (2 μM) as indicated for 12 h. d U2OS control, ACSL4−/−; GPX4−/− cells pre-incubated with Nutlin (10 μM) for 24 h were treated with TBH (250 μM), Nutlin (10 μM), Ferr-1 (2 μM), Lipro-1 (2 μM), 3-MA (2 mM), necrostatin-1 (10 μg/mL), and Z-VAD-FMK (10 μg/mL) as indicated, for 8 h. 3-MA, 3-methylademine. b–d Error bars are mean ± s.d., n = 3 biologically independent experiments. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 BTP or CMH has similar effects as TBH does. a Variant compounds having similar functional group with TBH. b U2OS control, ACSL4−/−; GPX4−/− cells pre-incubated with Nutlin (10 μM) for 12 h were treated with BTP (300 μM), Nutlin (10 μM), and Ferr-1 (2 μM) as indicated for 8 h. BTP, butanone peroxide. c U2OS control, ACSL4−/−; GPX4−/− cells pre-incubated with Nutlin (10 μM) for 12 h were treated with CMH (200 μM), Nutlin (10 μM), and Ferr-1 (2 μM) as indicated for 8 h. CMH, cumene hydroperoxide. d Lipid peroxidation levels of U2OS control, ACSL4−/−; GPX4−/− cells pre-incubated with Nutlin (10 μM) for 12 h were treated with TBH (300 μM), Nutlin (10 μM), and Ferr-1 (2 μM) as indicated for 8 h. e Quantification of lipid peroxidation levels is shown as in (d). b, c, e Error bars are mean ± s.d., n = 3 independent repeats. e All p values were calculated using two-tailed unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. For WT, p = 0.000000227, TBH versus Nutlin + TBH; p = 0.0000000407, Nutlin versus Nutlin + TBH. For ACSL4−/−; GPX4−/−, p = 0.000000000903, TBH versus Nutlin + TBH; p = 0.00000125, Nutlin versus Nutlin + TBH. Source data are provided as a Source Data file.
Fig. 2 BTP or CMH has similar effects as TBH does. a Variant compounds having similar functional group with TBH. b U2OS control, ACSL4−/−; GPX4−/− cells pre-incubated with Nutlin (10 μM) for 12 h were treated with BTP (300 μM), Nutlin (10 μM), and Ferr-1 (2 μM) as indicated for 8 h. BTP, butanone peroxide. c U2OS control, ACSL4−/−; GPX4−/− cells pre-incubated with Nutlin (10 μM) for 12 h were treated with CMH (200 μM), Nutlin (10 μM), and Ferr-1 (2 μM) as indicated for 8 h. CMH, cumene hydroperoxide. d Lipid peroxidation levels of U2OS control, ACSL4−/−; GPX4−/− cells pre-incubated with Nutlin (10 μM) for 12 h were treated with TBH (300 μM), Nutlin (10 μM), and Ferr-1 (2 μM) as indicated for 8 h. e Quantification of lipid peroxidation levels is shown as in (d). b, c, e Error bars are mean ± s.d., n = 3 independent repeats. e All p values were calculated using two-tailed unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. For WT, p = 0.000000227, TBH versus Nutlin + TBH; p = 0.0000000407, Nutlin versus Nutlin + TBH. For ACSL4−/−; GPX4−/−, p = 0.000000000903, TBH versus Nutlin + TBH; p = 0.00000125, Nutlin versus Nutlin + TBH. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 Regulation of iPLA2β during p53-mediated stress responses. a qPCR analysis of mRNA levels of iPLA2β in the MCF-7, U2OS, A375, and H1299 cells treated with 0.2 μg/mL doxorubicin or 10 μM Nutlin for 24 h. b qPCR analysis of mRNA levels of iPLA2β in the U2OS CRISPR control versus p53−/− cells treated with 10 μM Nutlin for 24 h. c Schematic representation of the promoter region in the human iPLA2β gene. The p53-binding sites upstream of the first exon are indicated as responsive elements (RE). TSS, transcription start site. d ChIP-qPCR was performed in H1299 cells transfected with empty vector or p53. p values were calculated using two-sided unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. p = 0.564 for RE1; p = 0.0000000196 for RE2; p = 0.000118 for RE3; and p = 0.00316 for TIGAR. e H1299 cells were transfected with empty vector, wild-type p53 or mutants (R175H, R273H, and R248W), and iPLA2β mRNA levels were analyzed by qRT-PCR. a, b, d, e Error bars are mean ± s.d., n = 3 biologically independent experiments. Source data are provided as a Source Data file.
Fig. 3 Regulation of iPLA2β during p53-mediated stress responses. a qPCR analysis of mRNA levels of iPLA2β in the MCF-7, U2OS, A375, and H1299 cells treated with 0.2 μg/mL doxorubicin or 10 μM Nutlin for 24 h. b qPCR analysis of mRNA levels of iPLA2β in the U2OS CRISPR control versus p53−/− cells treated with 10 μM Nutlin for 24 h. c Schematic representation of the promoter region in the human iPLA2β gene. The p53-binding sites upstream of the first exon are indicated as responsive elements (RE). TSS, transcription start site. d ChIP-qPCR was performed in H1299 cells transfected with empty vector or p53. p values were calculated using two-sided unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. p = 0.564 for RE1; p = 0.0000000196 for RE2; p = 0.000118 for RE3; and p = 0.00316 for TIGAR. e H1299 cells were transfected with empty vector, wild-type p53 or mutants (R175H, R273H, and R248W), and iPLA2β mRNA levels were analyzed by qRT-PCR. a, b, d, e Error bars are mean ± s.d., n = 3 biologically independent experiments. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 Differential effects on iPLA2β mediated by p53 depends on stress duration and intensity. a Western blot analysis of extracts of U2OS cells with different time of 10 μM Nutlin treatment. The experiments were repeated twice, independently, with similar results. b qPCR analysis of mRNA levels of iPLA2β for the above cells. c qPCR analysis of mRNA levels of SLC7A11 for the same cells as (a). d Western blot analysis of extracts of U2OS cells with different time of 10 μM Nutlin + TBH treatment. The experiments were repeated twice, independently, with similar results. e qPCR analysis of mRNA levels of iPLA2β for the same cells as (d). f qPCR analysis of mRNA levels of SLC7A11 for the same cells as (d). g Western blot analysis of extracts of HCT116 cells with low dose (lanes 1, 2) or high dose of doxorubicin (lanes 3, 4) as indicated for 30 h. The experiments were repeated twice, independently, with similar results. b, c, e, f Error bars are mean ± s.d., n = 3 biologically independent experiments. Source data are provided as a Source Data file.
Fig. 4 Differential effects on iPLA2β mediated by p53 depends on stress duration and intensity. a Western blot analysis of extracts of U2OS cells with different time of 10 μM Nutlin treatment. The experiments were repeated twice, independently, with similar results. b qPCR analysis of mRNA levels of iPLA2β for the above cells. c qPCR analysis of mRNA levels of SLC7A11 for the same cells as (a). d Western blot analysis of extracts of U2OS cells with different time of 10 μM Nutlin + TBH treatment. The experiments were repeated twice, independently, with similar results. e qPCR analysis of mRNA levels of iPLA2β for the same cells as (d). f qPCR analysis of mRNA levels of SLC7A11 for the same cells as (d). g Western blot analysis of extracts of HCT116 cells with low dose (lanes 1, 2) or high dose of doxorubicin (lanes 3, 4) as indicated for 30 h. The experiments were repeated twice, independently, with similar results. b, c, e, f Error bars are mean ± s.d., n = 3 biologically independent experiments. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 iPLA2β acts as a major suppressor of p53-mediated ferroptosis. a Western blot analysis of extracts of A375 CRISPR control (lanes 1, 2) versus p53 −/− cells (lanes 3, 4) treated with control RNAi (lanes 1, 3) or iPLA2β RNAi (lanes 2, 4) by the antibodies to iPLA2β, p53, p21, or actin. The experiments were repeated twice, independently, with similar results. b Quantification of ROS-induced ferroptotic cell death. The same cells in (a) were pre-incubated with 10 μM Nutlin for 24 h, then treated with 120 μM TBH and 10 μM Nutlin (error bars, s.d. from three independent samples). c Quantification of ferroptotic cell death-mediated by ROS. After iPLA2β RNAi treatment, MCF-7 cells were pre-incubated with 10 μM Nutlin for 24 h, then treated with 80 μM TBH and 10 μM Nutlin (error bars, s.d. from three independent samples). d Western blot analysis of extracts of A375 CRISPR control (lanes 1, 2), p53−/− cells (lanes 3, 4), iPLA2β−/− cells (lanes 5, 6), or p53−/−; iPLA2β−/− cells treated with Nutlin 10 μM for 24 h (lanes 2, 4, 6, 8) versus control (lanes 1,3, 5, 7) by the antibodies to iPLA2β, p53, p21, or actin. The experiments were repeated twice, independently, with similar results. e Quantification of cell death in the same cells as (d) with additional of 150 μm TBH as indicated. Error bars are mean ± s.d., n = 3 biologically independent experiments. f Quantification of ROS-mediated ferroptotic cell death. U2OS CRISPR control versus iPLA2β−/− cells pre-incubated with Nutlin (10 μM) for 24 h were treated with TBH (250 μM), Nutlin (10 μM) and Ferr-1 (2 μM) as indicated (error bars, s.d. from three independent replicates). Source data are provided as a Source Data file.
Fig. 5 iPLA2β acts as a major suppressor of p53-mediated ferroptosis. a Western blot analysis of extracts of A375 CRISPR control (lanes 1, 2) versus p53 −/− cells (lanes 3, 4) treated with control RNAi (lanes 1, 3) or iPLA2β RNAi (lanes 2, 4) by the antibodies to iPLA2β, p53, p21, or actin. The experiments were repeated twice, independently, with similar results. b Quantification of ROS-induced ferroptotic cell death. The same cells in (a) were pre-incubated with 10 μM Nutlin for 24 h, then treated with 120 μM TBH and 10 μM Nutlin (error bars, s.d. from three independent samples). c Quantification of ferroptotic cell death-mediated by ROS. After iPLA2β RNAi treatment, MCF-7 cells were pre-incubated with 10 μM Nutlin for 24 h, then treated with 80 μM TBH and 10 μM Nutlin (error bars, s.d. from three independent samples). d Western blot analysis of extracts of A375 CRISPR control (lanes 1, 2), p53−/− cells (lanes 3, 4), iPLA2β−/− cells (lanes 5, 6), or p53−/−; iPLA2β−/− cells treated with Nutlin 10 μM for 24 h (lanes 2, 4, 6, 8) versus control (lanes 1,3, 5, 7) by the antibodies to iPLA2β, p53, p21, or actin. The experiments were repeated twice, independently, with similar results. e Quantification of cell death in the same cells as (d) with additional of 150 μm TBH as indicated. Error bars are mean ± s.d., n = 3 biologically independent experiments. f Quantification of ROS-mediated ferroptotic cell death. U2OS CRISPR control versus iPLA2β−/− cells pre-incubated with Nutlin (10 μM) for 24 h were treated with TBH (250 μM), Nutlin (10 μM) and Ferr-1 (2 μM) as indicated (error bars, s.d. from three independent replicates). Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 iPLA2β acts as a major suppressor of p53-mediated tumor suppressor. a Xenograft tumors from A375 CRISPR control, iPLA2β−/−, p53−/− or p53−/−; iPLA2β−/− cells as indicated. b Tumor weights were determined from (a) (error bars, from eight tumors). The experiments were repeated twice independently with similar results and representative data were shown. p = 0.00049 for control versus iPLA2β−/−; p = 0.469 for p53−/− versus iPLA2β−/−; p53−/−. c qPCR of Ptgs2 mRNA from tumors harvested in (a). p = 0.00349 for control versus iPLA2β−/−. d A549 cells (Lanes 1, 2), p53−/− cells (lanes 3, 4), iPLA2β−/− cells (lanes 5, 6), or p53−/−; iPLA2β−/− cells (lanes 7, 8) treated with Nutlin 10 µM for 24 h (lanes 2, 4, 6, 8) versus control (lanes 1, 3, 5, 7) by the antibodies to iPLA2β, p53, p21or actin. The experiments were repeated twice, independently, with similar results. e Xenograft tumors from A549 CRISPR control, iPLA2β−/−, p53−/− or p53−/−; iPLA2β−/− cells as indicated. f Tumor weights were determined from (e) (error bars, from eight tumors). The experiments were repeated twice independently with similar results and representative data were shown. p = 0.00253 for A549 versus iPLA2β−/−; p = 0.686 for p53−/− versus iPLA2β−/−; p53−/−. g qPCR of Ptgs2 mRNA from tumors harvested in (e). p = 0.00000727 for A549 versus iPLA2β−/−. b, f Error bars are mean ± SEM. c, g Error bars are mean ± s.d., b–c, f–g n = 8 biologically independent samples. All p values were calculated using two-tailed unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. Source data are provided as a Source Data file.
Fig. 6 iPLA2β acts as a major suppressor of p53-mediated tumor suppressor. a Xenograft tumors from A375 CRISPR control, iPLA2β−/−, p53−/− or p53−/−; iPLA2β−/− cells as indicated. b Tumor weights were determined from (a) (error bars, from eight tumors). The experiments were repeated twice independently with similar results and representative data were shown. p = 0.00049 for control versus iPLA2β−/−; p = 0.469 for p53−/− versus iPLA2β−/−; p53−/−. c qPCR of Ptgs2 mRNA from tumors harvested in (a). p = 0.00349 for control versus iPLA2β−/−. d A549 cells (Lanes 1, 2), p53−/− cells (lanes 3, 4), iPLA2β−/− cells (lanes 5, 6), or p53−/−; iPLA2β−/− cells (lanes 7, 8) treated with Nutlin 10 µM for 24 h (lanes 2, 4, 6, 8) versus control (lanes 1, 3, 5, 7) by the antibodies to iPLA2β, p53, p21or actin. The experiments were repeated twice, independently, with similar results. e Xenograft tumors from A549 CRISPR control, iPLA2β−/−, p53−/− or p53−/−; iPLA2β−/− cells as indicated. f Tumor weights were determined from (e) (error bars, from eight tumors). The experiments were repeated twice independently with similar results and representative data were shown. p = 0.00253 for A549 versus iPLA2β−/−; p = 0.686 for p53−/− versus iPLA2β−/−; p53−/−. g qPCR of Ptgs2 mRNA from tumors harvested in (e). p = 0.00000727 for A549 versus iPLA2β−/−. b, f Error bars are mean ± SEM. c, g Error bars are mean ± s.d., b–c, f–g n = 8 biologically independent samples. All p values were calculated using two-tailed unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 7 Mechanistic insights into iPLA2β–mediated suppression of lipid peroxidation and ferroptosis induced by p53 and ROS stress. a Western blot analysis of U2OS ACSL4−/−; GPX4−/− cells transfected with AlOX12 or iPLA2β vector. The experiments were repeated twice, independently, with similar results. b Lipid peroxidation levels of U2OS ACSL4−/−; GPX4−/− cells transfected with ALOX12 or iPLA2β vector were treated with TBH (300 μM) and Ferr-1 (2 μM) as indicated for 8 h. c Quantification of lipid peroxidation levels as shown in (b). Error bars are mean ± s.d., n = 3 independent experiments. d Western blot analysis of U2OS ACSL4−/−; GPX4−/− cells transfected with iPLA2β or iPLA2γ vector. The experiments were repeated twice, independently, with similar results. e Quantification of Lipid peroxidation levels. U2OS ACSL4−/−; GPX4−/− cells with overexpression of iPLA2β or iPLA2γ were pre-incubated with Nutlin (10 μM) for 12 h, then treated with TBH (300 μM) and Nutlin (10 μM) as indicated for 8 h. f Quantification of cell death. U2OS ACSL4−/−; GPX4−/− cells with overexpression of iPLA2β or iPLA2γ were pre-incubated with Nutlin (10 μM) for 24 h, then treated with TBH (250 μM) and Nutlin (10 μM) as indicated. g Relative content of oxPE (18:0/22:4)sn2 in H1299 cells transfected with alox12, or/and iPLA2β (PE, phosphatidylethanolamines). p values were calculated using two-tailed unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. h Relative content of oxPE (18:0/20:4)sn2 in H1299 cells transfected ALOX12, or/and iPLA2β. i Quantification of cell death in H1299 cells transfected with vector, p53, iPLA2β WT or G517C, and additional TBH treatment. e–i Error bars are mean ± s.d., n = 3 biologically independent experiments. Source data are provided as a Source Data file.
Fig. 7 Mechanistic insights into iPLA2β–mediated suppression of lipid peroxidation and ferroptosis induced by p53 and ROS stress. a Western blot analysis of U2OS ACSL4−/−; GPX4−/− cells transfected with AlOX12 or iPLA2β vector. The experiments were repeated twice, independently, with similar results. b Lipid peroxidation levels of U2OS ACSL4−/−; GPX4−/− cells transfected with ALOX12 or iPLA2β vector were treated with TBH (300 μM) and Ferr-1 (2 μM) as indicated for 8 h. c Quantification of lipid peroxidation levels as shown in (b). Error bars are mean ± s.d., n = 3 independent experiments. d Western blot analysis of U2OS ACSL4−/−; GPX4−/− cells transfected with iPLA2β or iPLA2γ vector. The experiments were repeated twice, independently, with similar results. e Quantification of Lipid peroxidation levels. U2OS ACSL4−/−; GPX4−/− cells with overexpression of iPLA2β or iPLA2γ were pre-incubated with Nutlin (10 μM) for 12 h, then treated with TBH (300 μM) and Nutlin (10 μM) as indicated for 8 h. f Quantification of cell death. U2OS ACSL4−/−; GPX4−/− cells with overexpression of iPLA2β or iPLA2γ were pre-incubated with Nutlin (10 μM) for 24 h, then treated with TBH (250 μM) and Nutlin (10 μM) as indicated. g Relative content of oxPE (18:0/22:4)sn2 in H1299 cells transfected with alox12, or/and iPLA2β (PE, phosphatidylethanolamines). p values were calculated using two-tailed unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. h Relative content of oxPE (18:0/20:4)sn2 in H1299 cells transfected ALOX12, or/and iPLA2β. i Quantification of cell death in H1299 cells transfected with vector, p53, iPLA2β WT or G517C, and additional TBH treatment. e–i Error bars are mean ± s.d., n = 3 biologically independent experiments. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 8 The roles of ALOX12 and iPLA2β in regulating p53-mediated ferroptosis. a Western blot analysis of extracts of U2OS CRISPR control (lanes 1, 2) or FSP1−/− cells (lanes 3, 4) with overexpression of iPLA2β-V5 (lanes 2, 4) versus empty vector (lanes 1, 3) by the antibodies to FSP1, V5, or actin. The experiments were repeated twice, independently, with similar results. b Quantification of cell death in the same cells as (a) treated with 250 μM TBH after pretreatment with Nutlin 10 μM for 24 h. Error bars are mean ± s.d., n = 3 biologically independent experiments. c A model for the roles of ALOX12 and iPLA2β in regulating p53-mediated ferroptosis. d Kaplan-Meier survival curve was generated for overall survival by stratifying patient samples with kidney renal clear cell carcinoma (TCGA, PanCancer Atlas) from cBioPortal based on iPLA2β expression levels. High-expression group was defined as mRNA expression z-score > 1 (PLA2G6: EXP > 1). e Kaplan-Meier survival curve was generated for overall survival by stratifying patient samples with acute myeloid leukemia (TCGA, PanCancer Atlas) from cBioportal based on iPLA2β expression levels. d, e p values were calculated using two-sided unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. Source data are provided as a Source Data file.
Fig. 8 The roles of ALOX12 and iPLA2β in regulating p53-mediated ferroptosis. a Western blot analysis of extracts of U2OS CRISPR control (lanes 1, 2) or FSP1−/− cells (lanes 3, 4) with overexpression of iPLA2β-V5 (lanes 2, 4) versus empty vector (lanes 1, 3) by the antibodies to FSP1, V5, or actin. The experiments were repeated twice, independently, with similar results. b Quantification of cell death in the same cells as (a) treated with 250 μM TBH after pretreatment with Nutlin 10 μM for 24 h. Error bars are mean ± s.d., n = 3 biologically independent experiments. c A model for the roles of ALOX12 and iPLA2β in regulating p53-mediated ferroptosis. d Kaplan-Meier survival curve was generated for overall survival by stratifying patient samples with kidney renal clear cell carcinoma (TCGA, PanCancer Atlas) from cBioPortal based on iPLA2β expression levels. High-expression group was defined as mRNA expression z-score > 1 (PLA2G6: EXP > 1). e Kaplan-Meier survival curve was generated for overall survival by stratifying patient samples with acute myeloid leukemia (TCGA, PanCancer Atlas) from cBioportal based on iPLA2β expression levels. d, e p values were calculated using two-sided unpaired Student’s t-test. Detailed statistical tests are described in the ‘Methods’. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

Sorted by citations

Items 101–200 of 349

Related

See all

Metadata

Authors
Chen, D., Chu, B., Yang, X., Liu, Z., Jin, Y., Kon, N., Rabadan, R., Jiang, X., Stockwell, B. R., & Gu, W.
Affiliations
  • Herbert Irving Comprehensive Cancer Center (US)
  • Columbia University (US)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Gu, Wei
ORCID
Venue
Nature Communications
Publisher
Springer Science and Business Media LLC
Published
2021-06-15
Volume
12
Issue
1
Pages
3644-3644
ISSN
2041-1723 (ISSN-L)
DOI
10.1038/s41467-021-23902-6
PMC
PMC8206155
OpenAlex
W3168103972
Cited by
348
References
43
Citations by year
2026: 51 · 2025: 72 · 2024: 88 · 2023: 86 · 2022: 40 · 2021: 10
FWCI
36.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA216884, 5R01CA085533, 5R01CA254970, 5RO1CA224272)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Keywords
iPLA2β, phospholipase A2, ferroptosis, p53, lipid peroxidation, reactive oxygen species, tumor suppression, cancer therapy targets
MeSH terms
A549 Cells, Ferroptosis, Phospholipid Hydroperoxide Glutathione Peroxidase, Animals, Cell Survival, Disease Models, Animal, Fatty Acids, Female, Humans, Mice, Nude, Phospholipids, Tumor Suppressor Protein p53, Reactive Oxygen Species, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Group VI Phospholipases A2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review